Replies to post #274041 on Avid Bioservices Inc (CDMO)

[biopharm]

"...Presented data will include a biomarker in the SUNRISE trial that correlated with a statistically significant improvement in overall survival for patients treated with bavituximab in combination with docetaxel compared to patients treated with docetaxel alone. Peregrine will file a new patent application directed to the use of the biomarker prior to the presentation of results at the ESMO..."

and no one else could possibly patent this besides Peregrine, because no one else has PS Targeting rights

[entdoc]

4ourretirement: not so sure about that one. They should file the patent app. the next day!